Allakos Inc. (NASDAQ: ALLK) Stock Information | RedChip

Allakos Inc. (NASDAQ: ALLK)


$1.1600
+0.0100 ( -2.52% ) 218.5K

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Market Data


Open


$1.1600

Previous close


$1.1500

Volume


218.5K

Market cap


$101.85M

Day range


$1.1050 - $1.2200

52 week range


$0.5350 - $3.4050

SEC Filings


Form Type Description Pages Date
8-k 8K-related 11 Nov 18, 2024
8-k 8K-related 12 Nov 06, 2024
10-q Quarterly Reports 64 Nov 06, 2024
8-k 8K-related 12 Oct 10, 2024
8-k 8K-related 39 Oct 10, 2024
4 Insider transactions 1 Sep 12, 2024
4 Insider transactions 1 Sep 11, 2024
4 Insider transactions 1 Sep 10, 2024
4 Insider transactions 1 Sep 10, 2024
8-k 8K-related 11 Aug 16, 2024

Latest News